https://pharmadevicenews.com/galderma-wins-china-approval-for-relfydess-but-can-its-six-month-wrinkle-treatment-challenge-established-botox-rivals/ PharmaDeviceNews en 2026-10-23T06:56:09+00:00 Galderma wins China approval for Relfydess, but can its six-month wrinkle treatment challenge established Botox rivals? Alluzience, China, Dysport, Galderma Group AG, National Medical Products Administration, PEARL Technology, READY-1, relabotulinumtoxinA, Relfydess https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/eqt-offers-qiagen-shareholders-a-40-premium-but-can-its-e10-8bn-diagnostics-bet-unlock-faster-growth/ PharmaDeviceNews en 2026-10-23T06:32:10+00:00 EQT offers QIAGEN shareholders a 40% premium, but can its €10.8bn diagnostics bet unlock faster growth? Abu Dhabi Investment Authority, CPP Investments, Crown NL Bidco, EQT AB, EQT XI, QIAcuity, QIAGEN N.V., QIAstat-Dx, QuantiFERON, Thermo Fisher Scientific https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-Diagnostics-generic-1.webp https://pharmadevicenews.com/merck-and-moderna-report-42-lower-melanoma-recurrence-risk-in-phase-3-mrna-trial/ PharmaDeviceNews en 2026-10-23T06:24:49+00:00 Merck and Moderna report 42% lower melanoma recurrence risk in Phase 3 mRNA trial European Society for Medical Oncology, Georgina Long, INTerpath-001, intismeran autogene, KEYNOTE-942, Keytruda, Merck & Co., Moderna, pembrolizumab, United States Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-Cancer-generic.webp https://pharmadevicenews.com/drug-farm-reports-df-003-reduces-kidney-fibrosis-in-preclinical-alpk1-study/ PharmaDeviceNews en 2026-10-23T06:20:22+00:00 Drug Farm reports DF-003 reduces kidney fibrosis in preclinical ALPK1 study ALPK1, American Society of Nephrology, ASN Kidney Week, DF-003, Drug Farm, INSERM, Institut Pasteur, ROSAH syndrome, Université Paris Cité https://pharmadevicenews.com/wp-content/uploads/2026/07/Arcus-Biosciences-Q2-call-could-clarify-its-post-domvanalimab-development-strategy-e1784703447940.webp https://pharmadevicenews.com/gilead-sciences-makes-a-1-275bn-bet-on-an-early-stage-oral-drug-can-hcxt-2001-challenge-injectable-ibd-therapies/ PharmaDeviceNews en 2026-10-23T06:10:07+00:00 Gilead Sciences makes a $1.275bn bet on an early-stage oral drug. Can HCXT-2001 challenge injectable IBD therapies? Emvistegrast, Gilead Sciences, GS-1427, HCXT-2001, icotrokinra, Johnson & Johnson, PepStar Therapeutics https://pharmadevicenews.com/wp-content/uploads/2026/06/cAMPfield-targets-ulcerative-colitis-and-Crohns-disease-with-a-selective-PDE4B-strategy-e1781934419210.webp https://pharmadevicenews.com/innate-pharma-faces-a-crucial-november-update-can-its-adc-pipeline-and-sobi-deal-strengthen-its-position/ PharmaDeviceNews en 2026-10-22T04:04:06+00:00 Innate Pharma faces a crucial November update. Can its ADC pipeline and Sobi deal strengthen its position? AstraZeneca, Innate Pharma, IPH4502, IPH5201, lacutamab, monalizumab, PACIFIC-9, Swedish Orphan Biovitrum, TELLOMAK-3 https://pharmadevicenews.com/wp-content/uploads/2026/10/Innate-Pharma-November-Milestones-e1792641793412.webp https://pharmadevicenews.com/johnson-johnson-advances-surgical-ai-network-with-abu-dhabi-and-polyphonic-platform/ PharmaDeviceNews en 2026-10-22T03:40:26+00:00 Johnson & Johnson advances surgical AI network with Abu Dhabi and Polyphonic platform Amazon Web Services, Cleveland Clinic Abu Dhabi, Department of Health Abu Dhabi, Hub71, Johnson & Johnson, Johnson & Johnson MedTech, MONARCH, MONARCH QUEST, NVIDIA, Polyphonic https://pharmadevicenews.com/wp-content/uploads/2026/10/AI-Surgery-Arrives-in-Abu-Dhabi-e1792640364255.webp https://pharmadevicenews.com/olorofim-phase-3-results-show-fewer-kidney-complications-in-patients-with-invasive-aspergillosis/ PharmaDeviceNews en 2026-10-21T21:22:37+00:00 Olorofim Phase 3 results show fewer kidney complications in patients with invasive aspergillosis AmBisome, European Medicines Agency, F2G Ltd., Ltd., Olorofim, Shionogi & Co., U.S. Food and Drug Administration, University Hospitals Leuven https://pharmadevicenews.com/wp-content/uploads/2026/10/Aspergillosis-research-e1792617639916.webp https://pharmadevicenews.com/roivant-and-priovant-report-62-steroid-free-disease-control-with-brepocitinib-in-uveitis-trials/ PharmaDeviceNews en 2026-10-21T21:06:17+00:00 Roivant and Priovant report 62% steroid-free disease control with brepocitinib in uveitis trials AbbVie, Arbutus Biopharma, Genevant Sciences, LISRAYA, Moderna, Priovant Therapeutics, Roivant Sciences Ltd., U.S. Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/10/Ophthalmology-Images-e1792616628827.webp